Phospho-HNRNPD (Ser83) Antibody

What is Phospho-HNRNPD (Ser83) Antibody and what biological processes does it help study?

Phospho-HNRNPD (Ser83) Antibody is a rabbit polyclonal antibody that specifically recognizes the heterogeneous nuclear ribonucleoprotein D (hnRNPD) protein when phosphorylated at serine 83. hnRNPD, also known as AU-rich element RNA-binding protein 1 (AUF1), plays critical roles in RNA processing and gene expression regulation .

This antibody enables researchers to investigate several important biological processes including:

• RNA metabolism and stability regulation

• Pre-mRNA processing mechanisms

• Nucleocytoplasmic shuttling of RNA-binding proteins

• Post-translational modification effects on RNA-binding protein function

The hnRNPD protein contains two repeats of quasi-RRM domains that bind to RNAs and can localize to both the nucleus and cytoplasm. It specifically binds with high affinity to RNA molecules containing AU-rich elements (AREs) found within the 3'-UTR of many proto-oncogenes and cytokine mRNAs .

What species reactivity and applications are supported by commercially available Phospho-HNRNPD (Ser83) antibodies?

Available Phospho-HNRNPD (Ser83) antibodies demonstrate consistent reactivity patterns across manufacturers:

Most antibodies are validated for Western Blot (WB), Immunohistochemistry (IHC), and Immunofluorescence/Immunocytochemistry (IF/ICC) applications . Researchers should note that optimal dilutions vary by application and should be determined experimentally:

• WB: 1:500-1:3000

• IHC: 1:50-1:300

• IF/ICC: 1:100-1:1000

• ELISA: 1:20000

How should I design Western blot experiments to detect Phospho-HNRNPD (Ser83)?

When designing Western blot experiments to detect Phospho-HNRNPD (Ser83), consider the following methodological approach:

• Sample preparation:

  • Use fresh samples when possible, as phosphorylation states can degrade

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation

  • Consider using phosphatase treatments as negative controls

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal resolution

  • Load sufficient protein (30-50μg) to detect phosphorylated forms

  • Include molecular weight markers covering 35-45kDa range (hnRNPD expected at 38kDa)

• Transfer and blocking:

  • PVDF membranes are recommended for phosphorylated protein detection

  • Block with 5% BSA (not milk) in TBST, as milk contains phosphoproteins

• Antibody incubation:

  • Primary: Use 1:500-1:2000 dilution of Phospho-HNRNPD (Ser83) antibody

  • Secondary: Use appropriate HRP-conjugated anti-rabbit IgG

  • Consider using total HNRNPD antibody on separate blots for normalization

• Controls:

  • Include phosphatase-treated samples as negative controls

  • Use recombinant phosphorylated HNRNPD as positive control where available

  • Consider using cells treated with kinase activators/inhibitors

Interpreting results: The expected molecular weight of HNRNPD is approximately 38kDa. Alternative splicing produces four transcript variants that may appear as multiple bands .

What are the key considerations for optimizing immunofluorescence protocols with Phospho-HNRNPD (Ser83) antibody?

For successful immunofluorescence experiments with Phospho-HNRNPD (Ser83) antibody, researchers should consider these methodological factors:

• Fixation methods:

  • 4% paraformaldehyde (10-15 minutes) preserves phospho-epitopes better than methanol

  • Avoid extended fixation which may mask epitopes

• Permeabilization:

  • Use 0.2-0.5% Triton X-100 for nuclear proteins

  • Brief permeabilization (5-10 minutes) is typically sufficient

• Blocking and antibody dilutions:

  • Block with 5-10% normal serum from the secondary antibody host species

  • Start with 1:200-1:500 dilution of primary antibody

  • Incubate overnight at 4°C for optimal signal-to-noise ratio

• Controls and counterstaining:

  • Include secondary-only controls to assess background

  • Use DAPI for nuclear counterstaining

  • Consider co-staining with total HNRNPD antibody in separate channel

  • Phosphatase-treated samples can serve as negative controls

• Visualization and pattern interpretation:

  • HNRNPD localizes to both nucleus and cytoplasm

  • Phosphorylated form may show distinct distribution patterns

  • Look for potential colocalization with stress granule markers like TIA-1 when studying cellular stress responses

When interpreting results, note that phosphorylation status may change HNRNPD's subcellular distribution. Under normal conditions, expect predominantly nuclear localization with some cytoplasmic presence.

How can Cell-Based ELISA techniques be employed to quantify changes in HNRNPD phosphorylation at Ser83 under different cellular conditions?

Cell-Based ELISA provides a powerful method for quantifying changes in HNRNPD phosphorylation directly in cultured cells without the need for cell lysates. This approach is particularly valuable for time-course and drug-response studies.

Methodological approach:

• Experimental setup:

  • Seed cells in 96-well plates at optimal density (typically 1-5×10⁴ cells/well)

  • Allow attachment and growth to 70-80% confluence

  • Apply treatments (kinase activators/inhibitors, stress conditions, etc.)

  • Include untreated controls and time-point series as appropriate

• Cell-Based ELISA procedure:

  • Fix cells with 4% paraformaldehyde (10 minutes)

  • Permeabilize with 0.1-0.5% Triton X-100

  • Block with appropriate blocking buffer

  • Incubate with Phospho-HNRNPD (Ser83) antibody (follow manufacturer's recommendation)

  • Detect using HRP-conjugated secondary antibodies and appropriate substrate

• Normalization strategies (essential for accurate interpretation):

  • Normalize to total HNRNPD using non-phospho-specific antibody

  • Alternatively, use anti-GAPDH antibody as internal control

  • Cell density normalization via Crystal Violet staining

• Data analysis and interpretation:

  • Calculate phospho/total HNRNPD ratios

  • Apply appropriate statistical analysis for comparing treatments

  • Consider kinetics of phosphorylation/dephosphorylation

This approach offers advantages over traditional Western blotting by enabling higher throughput analysis and preserving cellular architecture. The hnRPD (phospho Ser83) Cell-Based ELISA Kit provides qualitative determination through an indirect ELISA format where phosphorylated hnRPD is captured by specific antibodies and detected via HRP-conjugated secondary antibodies .

What are the methodological approaches for investigating the functional significance of HNRNPD Ser83 phosphorylation in stress granule formation?

Investigating the functional significance of HNRNPD Ser83 phosphorylation in stress granule formation requires a multifaceted experimental approach:

• Stress granule induction and visualization:

  • Treat cells with known stress granule inducers (arsenite, heat shock, etc.)

  • Perform immunofluorescence with Phospho-HNRNPD (Ser83) antibody

  • Co-stain with established stress granule markers (TIA-1, G3BP1)

  • Quantify colocalization using appropriate imaging software

• Phosphorylation site mutation studies:

  • Generate S83A (phospho-deficient) and S83D/E (phospho-mimetic) HNRNPD mutants

  • Express these constructs in cells with HNRNPD knockdown background

  • Assess stress granule formation capacity under various stressors

  • Quantify size, number, and composition of stress granules

• Kinase inhibition experiments:

  • Identify candidate kinases that phosphorylate HNRNPD at Ser83

  • Use specific inhibitors to block phosphorylation

  • Monitor effects on stress granule dynamics

  • Perform rescue experiments with phospho-mimetic mutants

• RNA binding analysis:

  • Compare RNA binding profiles of phosphorylated vs. non-phosphorylated HNRNPD

  • Perform RNA immunoprecipitation followed by sequencing (RIP-seq)

  • Analyze changes in bound mRNA populations

• Functional readouts:

  • Assess mRNA stability of HNRNPD targets with and without Ser83 phosphorylation

  • Measure cell viability under stress conditions

  • Evaluate translational efficiency of target mRNAs

Previous research has demonstrated that antibodies to RNA binding proteins like hnRNP A1 can induce and localize to stress granules, suggesting potential mechanistic links between RNA-binding protein modifications and stress granule dynamics . Stress granules are recognized markers of neurodegeneration, highlighting the clinical relevance of these studies.

How should researchers interpret contradictory results between phospho-specific and total HNRNPD antibody signals in immunoblotting experiments?

When faced with contradictory results between phospho-specific and total HNRNPD antibody signals, researchers should systematically evaluate several potential explanations:

• Technical causes of discrepancies:

  • Epitope masking: Phosphorylation may alter protein conformation, affecting total antibody binding

  • Antibody specificity: Confirm the total antibody recognizes both phosphorylated and non-phosphorylated forms

  • Sample preparation issues: Phosphatase activity during extraction can reduce phospho-signal

  • Transfer efficiency differences: Phosphorylated proteins may transfer differently

• Biological explanations:

  • Redistribution: Phosphorylation may cause protein to relocate to insoluble fractions

  • Stability changes: Phosphorylation might alter protein half-life

  • Alternative splicing: Different isoforms may show different phosphorylation patterns

  • Competitive binding: Other proteins might selectively bind to phosphorylated forms

• Validation approaches:

  • Phosphatase treatment: Treat duplicate samples with phosphatase; phospho-signal should disappear while total signal remains

  • Titration experiments: Serial dilutions of samples can reveal non-linear relationships

  • Alternative antibodies: Use antibodies from different suppliers or that recognize different epitopes

  • Mass spectrometry: For definitive quantification of phosphorylated vs. total protein

• Quantification adjustments:

  • Instead of simple phospho/total ratios, consider using standards with known phosphorylation states

  • Account for potential differential affinity between antibodies

  • Report both absolute and relative changes in phosphorylation

Remember that different antibodies (even to the same target) may have vastly different affinities. The calculated ratios should therefore be used to compare relative changes across conditions rather than as absolute phosphorylation stoichiometry .

What are common troubleshooting strategies for weak or non-specific Phospho-HNRNPD (Ser83) signals in immunohistochemistry?

When encountering weak or non-specific signals in immunohistochemistry with Phospho-HNRNPD (Ser83) antibody, consider these methodological troubleshooting approaches:

• For weak or absent signals:

  • Antigen retrieval optimization: Try different methods (citrate buffer pH 6.0, EDTA buffer pH 9.0, or enzymatic retrieval)

  • Antibody concentration: Increase primary antibody concentration (try 1:50 dilution)

  • Incubation conditions: Extend primary antibody incubation to overnight at 4°C

  • Detection system: Switch to more sensitive detection method (polymer-HRP or tyramide signal amplification)

  • Sample fixation: Overfixation can mask epitopes; try reducing fixation time in future samples

  • Phosphorylation preservation: Ensure tissues were fixed rapidly; phospho-epitopes are labile

• For high background or non-specific signals:

  • Blocking optimization: Increase blocking time or try different blocking agents

  • Antibody dilution: Increase dilution of primary antibody (1:100 to 1:300)

  • Secondary antibody specificity: Test secondary alone to check for non-specific binding

  • Endogenous peroxidase quenching: Ensure complete quenching with 3% H₂O₂

  • Endogenous biotin blocking: If using biotin-based detection, block endogenous biotin

  • Tissue preparation: Ensure complete deparaffinization and rehydration

• Controls and validation:

  • Peptide competition: Pre-incubate antibody with immunizing phosphopeptide to confirm specificity

  • Phosphatase controls: Treat sections with phosphatase to confirm phospho-specificity

  • Positive control tissues: Include tissues known to express phosphorylated HNRNPD

  • Alternative antibody: Test another Phospho-HNRNPD (Ser83) antibody from a different supplier

• Special considerations for phospho-epitopes:

  • Phosphatase inhibitors: Add to all buffers during tissue processing

  • Section thickness: Thinner sections (4μm) may improve antibody penetration

  • Fresh tissues: Phospho-epitopes degrade over time in stored paraffin blocks

Remember that the optimal dilution range for IHC applications is typically between 1:50-1:300, but this must be empirically determined for each application and tissue type .

What is the functional significance of HNRNPD Ser83 phosphorylation in RNA metabolism and disease progression?

The phosphorylation of HNRNPD at Ser83 appears to have significant functional implications for RNA metabolism and potential disease associations:

• Impact on RNA binding and stability:

  • Phosphorylation may alter HNRNPD's affinity for AU-rich elements (AREs) in target mRNAs

  • This modification could affect the stability of mRNAs encoding cytokines and proto-oncogenes

  • Changes in RNA-binding properties may influence post-transcriptional gene regulation

  • Altered regulation of target mRNAs could contribute to disease pathogenesis

• Subcellular localization and protein interactions:

  • Phosphorylation potentially regulates nucleocytoplasmic shuttling of HNRNPD

  • Modified HNRNPD may interact differently with other RNA-binding proteins

  • Altered localization could affect assembly of ribonucleoprotein complexes

  • These changes may impact stress granule formation and composition

• Disease associations:

  • Research suggests connections to neurodegenerative processes via stress granule dynamics

  • Anti-RNA binding protein antibodies (such as anti-hnRNP A1) have been shown to induce stress granules, which are markers of neurodegeneration

  • Studies have linked altered hnRNP function to multiple sclerosis progression

  • Changes in RNA metabolism are increasingly recognized in cancer progression

• Cellular stress response:

  • Phosphorylation status may change during cellular stress responses

  • Modified HNRNPD could participate in stress granule formation

  • This modification might regulate selective translation during stress

  • Dysregulation of this process could contribute to pathological stress responses

Understanding the precise functional consequences of HNRNPD Ser83 phosphorylation remains an active area of research. Future studies using phospho-specific antibodies, combined with techniques like RNA-seq and ribosome profiling, will help clarify the regulatory networks affected by this specific post-translational modification .

How might advances in phosphoproteomics methodologies enhance our understanding of HNRNPD phosphorylation beyond Ser83?

Advanced phosphoproteomics approaches offer powerful new avenues for exploring HNRNPD phosphorylation comprehensively:

• Mass spectrometry-based phosphosite mapping:

  • High-resolution MS/MS can identify all phosphorylation sites on HNRNPD

  • Quantitative phosphoproteomics can determine stoichiometry of phosphorylation

  • Temporal dynamics of multiple phosphorylation events can be tracked

  • Cross-talk between Ser83 and other phosphosites can be evaluated

• Integrated multi-omics approaches:

  • Combine phosphoproteomics with transcriptomics and RNA-binding studies

  • Correlate phosphorylation patterns with RNA-binding profiles

  • Link phosphorylation states to downstream gene expression changes

  • Develop network models of phosphorylation-dependent RNA regulation

• Kinase-substrate relationship mapping:

  • Identify specific kinases responsible for each phosphorylation site

  • Develop kinase inhibitor strategies for functional validation

  • Map phosphorylation into cellular signaling pathways

  • Create predictive models of phosphorylation under various conditions

• Structural biology integration:

  • Determine how phosphorylation affects HNRNPD protein structure

  • Use cryo-EM to visualize phosphorylation-dependent ribonucleoprotein complexes

  • Apply molecular dynamics simulations to predict conformational changes

  • Design phospho-specific interaction inhibitors for therapeutic applications

• Single-cell phosphoproteomics:

  • Analyze cell-to-cell variation in HNRNPD phosphorylation

  • Identify rare cell populations with unique phosphorylation patterns

  • Track phosphorylation changes during cellular differentiation

  • Correlate with single-cell transcriptomics data

These advanced methodologies will move beyond the current focus on Ser83 to develop a comprehensive understanding of how multiple phosphorylation events collectively regulate HNRNPD function in health and disease. Current antibody-based approaches like those using Phospho-HNRNPD (Ser83) antibodies represent important tools but provide only a partial view of the complex phosphorylation landscape that likely controls this important RNA-binding protein .